Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma

Journal of Human Hypertension

Volumn 25, Issue 10, 2011, Pages 592-599

  Pimenta, E ^a   Gordon, R D ^a   Ahmed, A H ^a   Cowley, D ^a   Robson, D ^a   Kogovsek, C ^a   Stowasser, M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

aldosterone; kidney; proteinuria; salt

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; METHYLDOPA; MINERALOCORTICOID ANTAGONIST; PRAZOSIN; SPIRONOLACTONE; VERAPAMIL;

ADENOMA; ADRENALECTOMY; ADULT; ALDOSTERONE PRODUCING ADENOMA; ALDOSTERONE URINE LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY INJURY; MALE; POSTOPERATIVE PERIOD; PRIMARY HYPERALDOSTERONISM; PROTEIN URINE LEVEL; SALT INTAKE; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; URINARY EXCRETION;

ADENOMA; ADRENALECTOMY; ADULT; ALDOSTERONE; BLOOD PRESSURE; FEMALE; FLUDROCORTISONE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PROTEINURIA; SODIUM;

EID: 80052871365     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.102     Document Type: Article

References (61)

1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45(1): 3-17.
2. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(9): 3266-3281.
3. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich) 2006; 8(12): 887-893.
4. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21(11): 2149-2157. (Pubitemid 38296877)
5. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hyper-tens 2000; 14(5): 311-315. (Pubitemid 30311512)
6. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42(2): 161-165. (Pubitemid 36944590)
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48(11): 2293-2300. (Pubitemid 44873058)
8. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldoster-one Syst 2001; 2(3): 156-169. (Pubitemid 33685887)
9. Stowasser M, Gordon RD. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217(1-2): 33-39. (Pubitemid 38596626)
10. Sukor N, Kogovsek C, Gordon RD, Robson D, Stow-asser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalect-omy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010; 95(3): 1360-1364.
11. Stowasser M, Klemm SA, Tunny TJ, Storie WJ, Rutherford JC, Gordon RD. Response to unilateral adrenalect-omy for aldosterone-producing adenoma: effect of potassium levels and angiotensin responsiveness. Clin Exp Pharmacol Physiol 1994; 21(4): 319-322. (Pubitemid 24201226)
12. Rutherford JC, Taylor WL, Stowasser M, Gordon RD. Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 1998; 22(12): 1243-1245. (Pubitemid 28514344)
13. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83(6): 1849-1865.
14. Young M, Fullerton M, Dilley R, Funder J. Miner-alocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93(6): 2578-2583.
15. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141(10): 3871-3878.
16. Rocha R, Chander PN, Zuckerman A, Stier Jr CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33(1 Part 2): 232-237. (Pubitemid 29065665)
17. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63(5): 1791-1800. (Pubitemid 36513325)
18. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27(5): 303-310. (Pubitemid 38832669)
19. Abbate M, Benigni A, Bertani T, Remuzzi G. Nephro-toxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999; 14(2): 304-312. (Pubitemid 29062783)
20. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249(6): 519-526. (Pubitemid 32823860)
21. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephro-pathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63(1): 225-232. (Pubitemid 35463925)
22. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69(7): 1264-1271.
23. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332(7555): 1426.
24. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardio-vascular mortality in general population. Circulation 2002; 106(14): 1777-1782.
25. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G et al. Renal damage in primary aldoster-onism: results of the PAPY Study. Hypertension 2006; 48(2): 232-238. (Pubitemid 44309817)
26. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13(12 Part 2): 1801-1802. (Pubitemid 26015820)
27. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16(5): 1320-1325. (Pubitemid 41716516)
28. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishiza-ka MK, Aban I, Oparil S et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008; 51(2): 339-344. (Pubitemid 351159948)
29. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-1252. (Pubitemid 37553153)
30. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18(7): 495-511.
31. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldos-teronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207(2): 565-571.
32. Stowasser M, Gordon RD. The aldosterone-renin ratio in screening for primary aldosteronism. Endocrino-logist 2004; 14(5): 267-276. (Pubitemid 39232121)
33. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969; 29(10): 1349-1355.
34. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22(2): 377-381. (Pubitemid 38250998)
35. Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab 1970; 30(5): 682-685.
36. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50(9): 1650-1655. (Pubitemid 39121234)
37. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295(22): 2638-2645. (Pubitemid 43882339)
38. Catena C, Colussi G, Sechi LA. Renal function in primary aldosteronism. Hypertension 2006; 48(6): e110; author reply e111.
39. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006; 69(11): 2064-2069. (Pubitemid 43924272)
40. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25(6): 1339-1344.
41. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23(2): 195-199. (Pubitemid 24050280)
42. Sanders PW. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009; 297(2): F237-F243.
43. Sanders PW. Dietary salt intake, salt sensitivity, and cardiovascular health. Hypertension 2009; 53(3): 442-445.
44. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283(5): H1802-H1810. (Pubitemid 35217013)
45. Geerling JC, Loewy AD. Central regulation of sodium appetite. Exp Physiol 2008; 93(2): 177-209.
46. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66(1): 1-9. (Pubitemid 38870076)
47. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al. Nongenomic vascular action of aldoster-one in the glomerular microcirculation. J Am Soc Nephrol 2003; 14(9): 2255-2263. (Pubitemid 37052371)
48. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, Sorensen GL et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldos-terone. Circ Res 2003; 93(12): 1258-1266. (Pubitemid 37547959)
49. Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED. Salt loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 292(2): H814-H819.
50. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98(23): 2621-2628. (Pubitemid 29001204)
51. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45(8): 1243-1248. (Pubitemid 40523144)
52. Tuomilehto J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 2001; 357(9259): 848-851. (Pubitemid 32239370)
53. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91(2): 454-459. (Pubitemid 43236909)
54. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48(2): 239-245. (Pubitemid 44309818)
55. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteron-ism: a controlled cross-sectional study. Hypertension 2009; 53(4): 605-610.
56. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension 2009; 53(4): 585-586.
57. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168(1): 80-85.
58. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50(5): 911-918. (Pubitemid 350287534)
59. Young Jr WF. Primary aldosteronism-one picture is not worth a thousand words. Ann Intern Med 2009; 151(5): 357-358.
60. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151(5): 329-337.
61. Freel M, Ingram M, Fraser R, Dominiczak A, Davies E, Connell J. Aldosterone and sodium excess associate with albuminuria and glomerular hyperfiltration in a severely hypertensive cohort from the MRC BRIGHT Study. Hypertension 2009; 54(4): e51.